Cargando…
Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China
BACKGROUND: China implemented containment measures to stop SARS-CoV-2 transmission in response to the COVID-19 epidemic. After the first epidemic wave, we conducted population-based serological surveys to determine extent of infection, risk factors for infection, and neutralization antibody levels t...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864613/ https://www.ncbi.nlm.nih.gov/pubmed/33585828 http://dx.doi.org/10.1016/j.lanwpc.2021.100094 |
_version_ | 1783647690602577920 |
---|---|
author | Li, Zhongjie Guan, Xuhua Mao, Naiying Luo, Huiming Qin, Ying He, Na Zhu, Zhen Yu, Jianxing Li, Yu Liu, Jianhua An, Zhijie Gao, Wenjing Wang, Xiaoli Sun, Xiaodong Song, Tie Yang, Xingfen Wu, Ming Wu, Xianping Yao, Wenqing Peng, Zhibin Sun, Junling Wang, Liping Guo, Qing Xiang, Nijuan Liu, Jun Zhang, Bike Su, Xuemei Rodewald, Lance Li, Liming Xu, Wenbo Shen, Hongbing Feng, Zijian Gao, George F |
author_facet | Li, Zhongjie Guan, Xuhua Mao, Naiying Luo, Huiming Qin, Ying He, Na Zhu, Zhen Yu, Jianxing Li, Yu Liu, Jianhua An, Zhijie Gao, Wenjing Wang, Xiaoli Sun, Xiaodong Song, Tie Yang, Xingfen Wu, Ming Wu, Xianping Yao, Wenqing Peng, Zhibin Sun, Junling Wang, Liping Guo, Qing Xiang, Nijuan Liu, Jun Zhang, Bike Su, Xuemei Rodewald, Lance Li, Liming Xu, Wenbo Shen, Hongbing Feng, Zijian Gao, George F |
author_sort | Li, Zhongjie |
collection | PubMed |
description | BACKGROUND: China implemented containment measures to stop SARS-CoV-2 transmission in response to the COVID-19 epidemic. After the first epidemic wave, we conducted population-based serological surveys to determine extent of infection, risk factors for infection, and neutralization antibody levels to assess the real infections in the random sampled population. METHODS: We used a multistage, stratified cluster random sampling strategy to conduct serological surveys in three areas - Wuhan, Hubei Province outside Wuhan, and six provinces selected on COVID-19 incidence and containment strategy. Participants were consenting individuals >1 year old who resided in the survey area >14 days during the epidemic. Provinces screened sera for SARS-CoV-2-specific IgM, IgG, and total antibody by two lateral flow immunoassays and one magnetic chemiluminescence enzyme immunoassay; positive samples were verified by micro-neutralization assay. FINDINGS: We enrolled 34,857 participants (overall response rate, 92%); 427 were positive by micro-neutralization assay. Wuhan had the highest weighted seroprevalence (4•43%, 95% confidence interval [95%CI]=3•48%-5•62%), followed by Hubei-ex-Wuhan (0•44%, 95%CI=0•26%-0•76%), and the other provinces (<0•1%). Living in Wuhan (adjusted odds ratio aOR=13•70, 95%CI= 7•91–23•75), contact with COVID-19 patients (aOR=7•35, 95%CI=5•05–10•69), and age over 40 (aOR=1•36, 95%CI=1•07–1•72) were significantly associated with SARS-CoV-2 infection. Among seropositives, 101 (24%) reported symptoms and had higher geometric mean neutralizing antibody titers than among the 326 (76%) without symptoms (30±2•4 vs 15±2•1, p<0•001). INTERPRETATION: The low overall extent of infection and steep gradient of seropositivity from Wuhan to the outer provinces provide evidence supporting the success of containment of the first wave of COVID-19 in China. SARS-CoV-2 infection was largely asymptomatic, emphasizing the importance of active case finding and physical distancing. Virtually the entire population of China remains susceptible to SARS-CoV-2; vaccination will be needed for long-term protection. FUNDING: This study was supported by the Ministry of Science and Technology (2020YFC0846900) and the National Natural Science Foundation of China (82041026, 82041027, 82041028, 82041029, 82041030, 82041032, 82041033). |
format | Online Article Text |
id | pubmed-7864613 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-78646132021-02-09 Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China Li, Zhongjie Guan, Xuhua Mao, Naiying Luo, Huiming Qin, Ying He, Na Zhu, Zhen Yu, Jianxing Li, Yu Liu, Jianhua An, Zhijie Gao, Wenjing Wang, Xiaoli Sun, Xiaodong Song, Tie Yang, Xingfen Wu, Ming Wu, Xianping Yao, Wenqing Peng, Zhibin Sun, Junling Wang, Liping Guo, Qing Xiang, Nijuan Liu, Jun Zhang, Bike Su, Xuemei Rodewald, Lance Li, Liming Xu, Wenbo Shen, Hongbing Feng, Zijian Gao, George F Lancet Reg Health West Pac Research Paper BACKGROUND: China implemented containment measures to stop SARS-CoV-2 transmission in response to the COVID-19 epidemic. After the first epidemic wave, we conducted population-based serological surveys to determine extent of infection, risk factors for infection, and neutralization antibody levels to assess the real infections in the random sampled population. METHODS: We used a multistage, stratified cluster random sampling strategy to conduct serological surveys in three areas - Wuhan, Hubei Province outside Wuhan, and six provinces selected on COVID-19 incidence and containment strategy. Participants were consenting individuals >1 year old who resided in the survey area >14 days during the epidemic. Provinces screened sera for SARS-CoV-2-specific IgM, IgG, and total antibody by two lateral flow immunoassays and one magnetic chemiluminescence enzyme immunoassay; positive samples were verified by micro-neutralization assay. FINDINGS: We enrolled 34,857 participants (overall response rate, 92%); 427 were positive by micro-neutralization assay. Wuhan had the highest weighted seroprevalence (4•43%, 95% confidence interval [95%CI]=3•48%-5•62%), followed by Hubei-ex-Wuhan (0•44%, 95%CI=0•26%-0•76%), and the other provinces (<0•1%). Living in Wuhan (adjusted odds ratio aOR=13•70, 95%CI= 7•91–23•75), contact with COVID-19 patients (aOR=7•35, 95%CI=5•05–10•69), and age over 40 (aOR=1•36, 95%CI=1•07–1•72) were significantly associated with SARS-CoV-2 infection. Among seropositives, 101 (24%) reported symptoms and had higher geometric mean neutralizing antibody titers than among the 326 (76%) without symptoms (30±2•4 vs 15±2•1, p<0•001). INTERPRETATION: The low overall extent of infection and steep gradient of seropositivity from Wuhan to the outer provinces provide evidence supporting the success of containment of the first wave of COVID-19 in China. SARS-CoV-2 infection was largely asymptomatic, emphasizing the importance of active case finding and physical distancing. Virtually the entire population of China remains susceptible to SARS-CoV-2; vaccination will be needed for long-term protection. FUNDING: This study was supported by the Ministry of Science and Technology (2020YFC0846900) and the National Natural Science Foundation of China (82041026, 82041027, 82041028, 82041029, 82041030, 82041032, 82041033). Elsevier 2021-02-05 /pmc/articles/PMC7864613/ /pubmed/33585828 http://dx.doi.org/10.1016/j.lanwpc.2021.100094 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Li, Zhongjie Guan, Xuhua Mao, Naiying Luo, Huiming Qin, Ying He, Na Zhu, Zhen Yu, Jianxing Li, Yu Liu, Jianhua An, Zhijie Gao, Wenjing Wang, Xiaoli Sun, Xiaodong Song, Tie Yang, Xingfen Wu, Ming Wu, Xianping Yao, Wenqing Peng, Zhibin Sun, Junling Wang, Liping Guo, Qing Xiang, Nijuan Liu, Jun Zhang, Bike Su, Xuemei Rodewald, Lance Li, Liming Xu, Wenbo Shen, Hongbing Feng, Zijian Gao, George F Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China |
title | Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China |
title_full | Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China |
title_fullStr | Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China |
title_full_unstemmed | Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China |
title_short | Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China |
title_sort | antibody seroprevalence in the epicenter wuhan, hubei, and six selected provinces after containment of the first epidemic wave of covid-19 in china |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864613/ https://www.ncbi.nlm.nih.gov/pubmed/33585828 http://dx.doi.org/10.1016/j.lanwpc.2021.100094 |
work_keys_str_mv | AT lizhongjie antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT guanxuhua antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT maonaiying antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT luohuiming antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT qinying antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT hena antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT zhuzhen antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT yujianxing antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT liyu antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT liujianhua antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT anzhijie antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT gaowenjing antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT wangxiaoli antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT sunxiaodong antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT songtie antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT yangxingfen antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT wuming antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT wuxianping antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT yaowenqing antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT pengzhibin antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT sunjunling antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT wangliping antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT guoqing antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT xiangnijuan antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT liujun antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT zhangbike antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT suxuemei antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT rodewaldlance antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT liliming antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT xuwenbo antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT shenhongbing antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT fengzijian antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina AT gaogeorgef antibodyseroprevalenceintheepicenterwuhanhubeiandsixselectedprovincesaftercontainmentofthefirstepidemicwaveofcovid19inchina |